The immunophenotype of 177 adults with acute myeloid leukemia: Proposal of a prognostic score

Blood

Volumn 96, Issue 3, 2000, Pages 870-877

  Legrand, O ^a   Perrot, J Y ^a   Baudard, M ^a   Cordier, A ^a   Lautier, R ^a   Simonin, G ^a   Zittoun, R ^a   Casadevall, N ^a   Marie, J P ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; MICROSOMAL AMINOPEPTIDASE; MYELOPEROXIDASE; STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOGENETICS; CYTOTOXICITY; FEMALE; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME;

EID: 0034254362     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.3.870     Document Type: Article

References (42)

1. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO)
2. A classification of acute leukaemia for the 1990s
3. Proposal for the immunological classification of acute leukemias. For the European Group for the immunological Characterization of Leukemias (EGIL)
4. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. For the European Group for the Immunological Classification of Leukaemias (EGIL)
5. Treatment and prognostic factors in acute myeloid leukemia
6. Clinical significance of surface antigen expression in children with acute myeloid leukemia
7. Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia
8. Prognostic value of immunophenotyping in acute myeloid leukemia
9. The prognostic significance of chromosomal analysis and immunophenotyping in 117 patients with de novo acute myeloid leukemia
10. Surface marker expression in adult acute myeloid leukaemia; Correlations with initial characteristics, morphology and response to therapy
11. The significance of CD34 and TdT determination in patients with untreated de novo acute myeloid leukemia
12. Prognostic value of cell marker analysis in de novo acute myeloid leukemia
13. Surface markers in adult acute myeloblastic leukemia: Correlation of CD19+, CD34+ and CD14+/DR-phenotypes with shorter survival Groupe d'Etude Immunologique des Leucemies (GEIL)
14. Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia
15. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: Analysis of prognostic factors
16. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients
17. Methods to detect P-glycoprotein-associated multidrug resistance in patient tumors: Consensus recommendations
18. For the French Network of the Drug Resistance Intergroup and Drug Resistance Network of 'Assistance Publique-Hopitaux de Paris'. Multicentric evaluation of the MDR phenotype in leukemia
19. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia
20. In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukemia
21. Chemosensitivity testing: Another chapter
22. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia
23. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia
24. Mono-nuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay
25. Non-parametric estimation from incomplete observations
26. Regression models and life tables (with discussion)
27. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics
28. Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials: MRC Adult Leukaemia Working Party
29. Frequency of CBF beta/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials: The MRC Adult Leukaemia Working Party
30. Molecular detection of t(8;21)/AML1-ETO in AML M1/M2: Correlation with cytogenetics, morphology and immunophenotype
31. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells
32. MDR1/P-glycoprotein in haematological neoplasms
33. Expression of MDR1 gene in acute leukemia cells: Association with CDT+ acute myeloblastic leukemia/acute lymphoblastic leukemia
34. Relationship between MDR1 gene and surface markers in acute myeloid leukemia
35. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics